Company / SG&A Expense
Benitec Biopharma Inc. SG&A Expense History
FY2020-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$5.6M
FY2021
5-year range
$4.6M / $5.6M
FY2020-FY2021
Trend
+20.7%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$6M in FY2021.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2021, sg&a expense increased 20.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.32 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $5.6M | +20.7% |
| FY2020 | $4.6M | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026